Cambridge, UK-based EDX Medical is launching a diagnostic tool in the UK to identify patients at risk of developing genetic cancers.
This yet-to-be-named diagnostic tool involves germline testing. Although rare, mutations in tumors, particularly in prostate, breast, and colorectal cancers, can be inherited, which germline testing can help determine.
According to EDx, the pan-cancer test, which will be made available later this summer through private healthcare providers and some National Health Service (NHS) genetic testing centers, can achieve 99% sensitivity and identify mutations in 70 genes known to be associated with cancers with a strong genetic component.
“Testing family members of cancer patients should be a key part of the national cancer prevention and management strategy,” said Mike Hudson, CEO of EDx. “This testing enables doctors to identify important genetic risks shared by patients and their families, take preventive action before disease onset or make well-informed clinical decisions and ensure access to modern medicines with greater chances of long-term survival if cancer does occur later.”
In May 2024, ASCO released new recommendations about germline testing. The society stated that patients who would not normally be offered germline genetic testing based on personal or family history criteria, but who have pathogenic or likely pathogenic variants in their genes identified by tumor testing, should also be offered germline testing.
Last year, EDX partnered with Thermo Fisher for the joint development and potential commercialization of several clinical grade tests, including cancer diagnostic solutions.
Access the most comprehensive company profiles on the market, powered by GlobalData. Save hours of research. Gain a competitive edge.
Company Profile – Free Sample
Your download will arrive by email shortly
We are confident about the unique quality of our company profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the form below
by GlobalData
In the field of genetic testing, Chinese biotech MGI Tech and France's SecOne Genomics recently decided to work together to develop end-to-end solutions for genomic testing.
